8-K: 23andMe Reports Q1 Fiscal 2025 Results, Announces Therapeutics Restructuring and Executive Departure

23andMe's first quarter fiscal 2025 results show a 34% revenue decrease year-over-year, alongside a restructuring of its therapeutics division and the resignation of a key executive.

Summary

• 23andMe reported a total revenue of $40 million for the first quarter of fiscal year 2025, a 34% decrease compared to $61 million in the same period last year.
• The revenue decline was primarily due to lower research revenue following the end of the GSK collaboration exclusivity in July 2023, and reduced consumer revenue from decreased PGS kit volumes and telehealth orders.
• Operating expenses decreased to $92 million from $140 million year-over-year, driven by lower personnel costs and reduced R&D spending in the therapeutics area.
• The company's net loss improved to $69 million from $105 million in the prior year's first quarter.
• Adjusted EBITDA showed a loss of $35 million, an improvement from a $50 million loss in the same period last year.
• 23andMe ended the quarter with $170 million in cash and cash equivalents, down from $216 million at the end of the previous quarter.
• The company is launching a large-scale genetic research study on GLP-1 medications and plans to offer a GLP-1 weight loss telehealth membership.
• 23andMe is ceasing operations of the Therapeutics Discovery portion of its business, resulting in the termination of 30 employees.
• Bill Richards, Head of Therapeutics Discovery, resigned effective August 23, 2024, and will receive a severance package including a $253,500 lump sum payment and accelerated vesting of 90,265 RSUs.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While there are improvements in net loss and operating expenses, the significant revenue decline and restructuring of the therapeutics division are concerning. The resignation of a key executive also adds to the negative sentiment. The company is making strategic moves, but the overall financial picture is still weak.

Positives

• Operating expenses decreased significantly, driven by lower personnel costs and reduced R&D spending.
• Net loss improved year-over-year, indicating progress in controlling losses.
• Adjusted EBITDA loss improved, reflecting better operational efficiency.
• The company is expanding its offerings with a new genetic research study and telehealth membership focused on GLP-1 medications.
• 23andMe continues to build out its Total Health offering with the addition of a Biological Age feature.
• The company has launched a new genetic Polygenic Risk Score report for bipolar disorder for 23andMe+ members.

Negatives

• Total revenue decreased by 34% year-over-year, primarily due to the end of the GSK collaboration exclusivity and lower consumer sales.
• Cash and cash equivalents decreased from $216 million to $170 million during the quarter.
• The company is ceasing operations of its Therapeutics Discovery business, resulting in 30 employee terminations.
• The resignation of the Head of Therapeutics Discovery could impact the company's drug development efforts.

Risks

• The significant decrease in revenue raises concerns about the company's ability to achieve sustainable growth.
• The reduction in cash reserves could limit the company's ability to invest in future growth opportunities.
• The restructuring of the Therapeutics business and the departure of a key executive could disrupt ongoing projects and timelines.
• The company's reliance on consumer services revenue makes it vulnerable to changes in consumer demand and market trends.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company expects to launch a GLP-1 weight loss telehealth membership by the end of the month and is focused on prioritizing memberships in its PGS segment, driving growth in Telehealth, and leveraging its data assets to create a profitable Research Data business. The company is also continuing to work towards progressing its two therapeutics programs currently in clinical development.

Management Comments

• The first quarter saw us achieve significant progress on our key objective of becoming a sustainably growing, profitable company while remaining committed to our vision of improving the health of millions of people worldwide, said Anne Wojcicki, Co-Founder & CEO of 23andMe.
• We remain focused on adding value to and prioritizing memberships in our PGS segment, driving growth in Telehealth and leveraging our data assets to create a thriving, profitable Research Data business.

Industry Context

The announcement reflects a broader trend in the biotech industry where companies are focusing on core competencies and cutting costs to achieve profitability. The move to focus on telehealth and GLP-1 medications aligns with current market trends in weight management and personalized healthcare.

Comparison to Industry Standards

• The 34% revenue decrease is significant and suggests 23andMe is underperforming compared to some of its peers in the consumer genetics and biopharmaceutical space. For example, companies like Ancestry.com, while not directly comparable, have shown more stable revenue streams in the consumer genetics market.
• The reduction in operating expenses is a positive step, but the company's adjusted EBITDA loss of $35 million still indicates a need for further cost management. Companies like Myriad Genetics, which also operate in the genetic testing space, have been working towards achieving profitability through similar cost-cutting measures.
• The move to focus on GLP-1 medications and telehealth is a strategic shift that aligns with the current market demand. Companies like Teladoc Health have seen success in the telehealth space, and 23andMe's move could position them to capture a share of this growing market.
• The restructuring of the Therapeutics Discovery business is a significant change. Other companies in the biopharmaceutical space, such as Biogen, have also restructured their R&D efforts to focus on more promising programs. 23andMe's decision to focus on its two clinical programs is a similar move to streamline operations.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the significant revenue decline and the restructuring of the therapeutics business.
• Employees in the Therapeutics Discovery division have been impacted by the termination of 30 positions.
• Customers may see changes in the company's product offerings and services as the company focuses on its core business areas.
• Suppliers and creditors may be impacted by the company's financial performance and restructuring efforts.

Next Steps

• The company will launch a GLP-1 weight loss telehealth membership by the end of the month.
• The company will continue to progress its two therapeutics programs currently in clinical development.
• The company will focus on prioritizing memberships in its PGS segment and driving growth in Telehealth.

Key Dates

Keywords

23andMe, genetics, therapeutics, revenue, EBITDA, research, telehealth, GLP-1, restructuring, severance, clinical trials, biopharmaceutical